EUCTR2014-005012-42-AT进行中（未招募）1 期
A Phase 4, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis.The COBALT Study Clinical Outcomes with OBeticholic Acid in Liver Treatment (COBALT)
Intercept Pharmaceuticals Inc.0 个研究点目标入组 428 人开始时间: 2015年9月28日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 428
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Definite or probable PBC diagnosis (consistent with American
- •Association for the Study of Liver Diseases [AASLD] and the European
- •Association for the Study of the Liver [EASL] practice guidelines; Lindor
- •2009; EASL 2009), as demonstrated by the presence of =2 of the
- •following 3 diagnostic factors:
- •a. History of elevated Alkaline phosphatase levels for at least 6
- •b. Positive antimitochondrial antibody (AMA) titer or if AMA negative
- •or in low titer (<1:80) PBC-specific antibodies (anti-GP210 and/or anti-
- •SP100 and/or antibodies against the major M2 components [PDC-E2, 2-
- •oxo-glutaric acid dehydrogenase complex]).
- •c. Liver biopsy consistent with PBC.
- •2. A mean total bilirubin >ULN and =5x ULN and/or a mean ALP >3x
- •3. Either is not taking UDCA (no UDCA dose in the past =3 months) or
- •has been taking UDCA for at least 12 months with a stable dose for =3
- •months prior to Day 0.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 278
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •1. History or presence of other concomitant liver diseases including:
- •a. Hepatitis C virus infection
- •b. Active hepatitis B infection; however, subjects who have seroconverted (hepatitis B surface antigen and hepatitis B e antigen negative) may be included in this study after consultation with the medical monitor
- •c. Primary sclerosing cholangitis
- •d. Alcoholic liver disease
- •e. Definite autoimmune liver disease or overlap hepatitis
- •f. Nonalcoholic steatohepatitis
- •g. Gilbert’s Syndrome
- •2. Presence of clinical complications of PBC or clinically significant hepatic decompensation, including:
- •a. History of liver transplant, current placement on a liver transplant list, or current MELD score >12. Subjects who are placed on a transplant list despite a relatively early disease stage (for example per regional guidelines) may be eligible as long as they do not meet any of the other exclusion criteria
- •b. Cirrhosis with complications, including history (within the past 12 months) or presence of:
- •i. Variceal bleeding
- •ii. Uncontrolled ascites
- •iii. Encephalopathy
- •iv. Spontaneous bacterial peritonitis
- •c. Known or suspected hepatocellular carcinoma
- •d. Prior transjugular intrahepatic portosystemic shunt procedure
- •e. Hepatorenal syndrome (type I or II) or Screening (visit 1 or 2) serum creatinine >2 mg/dL (178 µmol/L)
- •3. Mean total biliburin >5x ULN
- •4. Subjects who have undergone gastric bypass procedures (gastric lap band is acceptable) or ileal resection or plan to undergo either of these procedures
- •5. Other medical conditions that may diminish life expectancy, including known cancers (except carcinomas in situ or other stable, relatively benign conditions)
- •6. If female: plans to become pregnant, known pregnancy or a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating
- •7. Known history of human immunodeficiency virus infection
- •8. Medical conditions that may cause nonhepatic increases in ALP (eg, Paget's disease or fractures within 3 months prior to Day 0)
- •9. Other clinically significant medical conditions that are not well controlled or for which medication needs are anticipated to change during the study
- •10. History of alcohol abuse or other substance abuse within 1 year prior to Day 0
- •11. Participation in another investigational product, biologic, or medical device study within 30 days prior to Screening. Participation in a previous study of OCA is allowed with 3 months washout prior to enrollment in this study
- •12. Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain
- •13. History of known or suspected clinically significant hypersensitivity to OCA or any of its components
- •14. UDCA naïve (unless contraindicated)
研究者
相似试验
进行中（未招募）
1 期
A Phase 4 clinical trial to measure the effect of Obeticholic acid against a placebo, in conjunction with standard treatment, on selected clinical measurements in patients with the liver disease, Primary Biliary Cholangitis. The COBALT Study Clinical Outcomes with OBeticholic Acid in Liver Treatment (COBALT).MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2014-005012-42-NLIntercept Pharmaceuticals Inc.428
招募中
不适用
Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary CirrhosisDiseases of the digestive systemKCT0001917Intercept Pharmaceuticals428
进行中（未招募）
1 期
A Phase 4 clinical trial to measure the effect of Obeticholic acid against aplacebo, in conjunction with standard treatment, on selected clinicalmeasurements in patients with the liver disease, Primary BiliaryCholangitis.The COBALT Study Clinical Outcomes with OBeticholic Acid in LiverTreatment (COBALT).MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2014-005012-42-FIIntercept Pharmaceuticals Inc.428
进行中（未招募）
1 期
A Phase 4 clinical trial to measure the effect of Obeticholic acid against a placebo, in conjunction with standard treatment, on selected clinical measurements in patients with the liver disease, Primary Biliary Cholangitis.The COBALT Study Clinical Outcomes with OBeticholic Acid in Liver Treatment (COBALT).MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2014-005012-42-BEIntercept Pharmaceuticals Inc.334
进行中（未招募）
1 期
A Phase 4 clinical trial to measure the effect of Obeticholic acid against a placebo, in conjunction with standard treatment, on selected clinical measurements in patients with the liver disease, Primary Biliary Cholangitis.The COBALT Study Clinical Outcomes with Obeticholic Acid in Liver Treatment (COBALT)MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2014-005012-42-EEIntercept Pharmaceuticals Inc.428